Condition: NSCLC Stage IV · Sponsor: ImmunityBio, Inc.
This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) CPI and docetaxel (cohort B) versus docetaxel monotherapy (cohorts A and B). For each cohort, enrolled participants will be randomized 2:1 to treatment in the experimental arm or the control arm. For cohort A, the randomization will be stratified by geographical region (North America vs Europe vs Asia vs Other), NSCLC histology (squamous vs nonsquamous), and actionable genomic alteration (AGA) (epidermal growth factor receptor \[EGFR\]/anaplastic lymphoma kinase \[ALK\]/ROS proto-oncogene 1, receptor tyrosine kinase \[ROS1\] vs Other AGA vs No AGA). For cohort B, the randomization will be stratified by geographical region (Americas vs Asia Pacific \[PAC\] vs Other), NSCLC histology (squamous vs nonsquamous), and actionable genomic alteration (AGA) (Yes vs No).
This description comes directly from the study's public registry record.
Phillip Trieu · 856-739-5609 · Phillip.Trieu@immunitybio.com
Tamra Madenwald · Tamra.Madenwald@immunitybio.com
Always discuss trial participation with your own doctor first.
| Highlands Oncology Group | Springdale, Arkansas, United States | Recruiting |
| Chan Soon-Shiong Institute for Medicine | El Segundo, California, United States | Recruiting |
| MemorialCare - Orange Coast Medical Center | Fountain Valley, California, United States | Recruiting |
| OPN Healthcare INC | Glendale, California, United States | Completed |
| OPN Healthcare INC/ Cancer and Blood Specialty Clinic | Los Alamitos, California, United States | Completed |
| Holy Cross Hospital | Fort Lauderdale, Florida, United States | Recruiting |
| The Oncology Institute of Hope and Innovation | Fort Lauderdale, Florida, United States | Recruiting |
| Moffit Cancer Center | Tampa, Florida, United States | Recruiting |
| Emory University - Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Barnes-Jewish Hospital - Siteman Cancer Center (Washington University - St. Louis) | St Louis, Missouri, United States | Recruiting |
| Carolina Oncology Specialists | Hickory, North Carolina, United States | Recruiting |
| University of Cincinnati Medical Center | Cincinnati, Ohio, United States | Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06745908